Forteo患者登记与多个州癌症登记处链接:研究设计及前8年结果
Forteo患者登记(FPR)是一项美国前瞻性登记研究,旨在估计接受特立帕肽治疗患者中骨肉瘤的发病率。截至2017年第八次年度链接,共63,270例患者、约242,782人年的随访中未发现骨肉瘤病例。预计至2024年研究结束可检测到骨肉瘤风险的四倍增加(若存在)。
要点
- FPR旨在估计美国接受特立帕肽治疗患者中骨肉瘤的发病率。
- 截至第八次年度链接(2017年),63,270例患者约242,782人年随访中未发现骨肉瘤病例。
- 预计至2024年研究结束可检测骨肉瘤风险的四倍增加(若存在)。
核心结论
- 基于第八次年度链接时约242,782人年的观察,并将当前入组率推算至2024年研究结束,预计完成的研究若存在骨肉瘤风险四倍增加则能够检测到。
- 至今在FPR登记的患者中未发现骨肉瘤 incident 病例。
研究设计与样本
- FPR是一项美国前瞻性登记研究,旨在将参与者数据与州癌症登记处进行年度链接。
- 患者入组计划为期10年(2009-2019年),与US州癌症登记处的年度链接计划为期15年(2010-2024年)。
- 所有US州癌症登记处和DC均被邀请参与。
- 患者通过特立帕肽设备包装、套件和医疗保健提供者分发的小册子中的预入组材料、免费电话号码和研究网站招募。
- 使用链接算法将入组参与者的数据与癌症登记处数据进行匹配。
主要发现
- 2017年第八次年度链接时,向42个参与登记处各提交了63,270例FPR患者进行链接所需的信息。
- 这些患者贡献了约242,782人年的随访。
- 参与州癌症登记处共提供自2009年1月1日以来诊断的5268例成人骨肉瘤病例用于链接。
- 至今在FPR登记的患者中未发现骨肉瘤 incident 病例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The Forteo Patient Registry (FPR) aims to estimate the incidence of osteosarcoma in US patients treated with teriparatide. Enrollment began in 2009 and will continue through 2019, with linkage planned through 2024. To date, no incident cases of osteosarcoma have been identified among patients registered in the FPR. INTRODUCTION: The Forteo Patient Registry (FPR) was established in 2009 to estimate the incidence of osteosarcoma in US patients treated with teriparatide. The objective of this paper is to describe study methods, challenges encountered, and progress to date. METHODS: The FPR is a prospective US registry designed to link data from participants annually with state cancer registries. Patient enrollment is planned for 10 years (2009-2019) and annual linkage with US state cancer registries for 15 years (2010-2024). All US state cancer registries and DC were invited to participate. Patients are recruited using pre-enrollment materials included in teriparatide device packaging, kits, and brochures distributed by health-care providers; a toll-free number; and a study website. A linkage algorithm is used to match data from enrolled participants with cancer registry data. RESULTS: For the eighth annual linkage in 2017, information necessary for linkage with 63,270 patients in the FPR was submitted to each of the 42 participating registries. These patients contributed approximately 242,782 person-years of follow-up. A total of 5268 adult osteosarcoma cases diagnosed since January 1, 2009, were available for linkage from participating state cancer registries. To date, no incident cases of osteosarcoma have been identified among patients registered in the FPR. CONCLUSIONS: Based on the estimated 242,782 person-years of observation as of the eighth annual linkage and projecting current enrollment rate to study end in 2024, it is anticipated that the completed study will be able to detect a fourfold increase in the risk of osteosarcoma if one exists.
引用
- Gilsenan A, Harding A, Kellier-Steele N, et al. The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years. Osteoporos Int. 2018. PMID: 29978254. doi:10.1007/s00198-018-4604-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。